MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novartis AG

Fermé

112.41 1.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

110.38

Max

114.32

Chiffres clés

By Trading Economics

Revenu

-369M

2.8B

Ventes

386M

14B

P/E

Moyenne du Secteur

18.992

63.778

BPA

1.98

Rendement du dividende

3.47

Marge bénéficiaire

20.8

Employés

75,883

EBITDA

-426M

5.2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+0.21% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.47%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.9B

221B

Ouverture précédente

110.96

Clôture précédente

112.41

Score Technique

By Trading Central

Confiance

Bearish Evidence

Novartis AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 févr. 2025, 06:57 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 janv. 2025, 09:49 UTC

Résultats

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 janv. 2025, 08:06 UTC

Résultats

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 janv. 2025, 06:32 UTC

Résultats

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 mars 2025, 07:34 UTC

Market Talk

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 mars 2025, 18:45 UTC

Résultats

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 févr. 2025, 09:25 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 févr. 2025, 06:42 UTC

Actualités
Acquisitions, Fusions, Rachats

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 févr. 2025, 06:22 UTC

Acquisitions, Fusions, Rachats

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 févr. 2025, 06:20 UTC

Acquisitions, Fusions, Rachats

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 févr. 2025, 06:19 UTC

Acquisitions, Fusions, Rachats

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 févr. 2025, 06:18 UTC

Acquisitions, Fusions, Rachats

Novartis: Deal Is Expected to Close in 1H of 2025

11 févr. 2025, 06:18 UTC

Acquisitions, Fusions, Rachats

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 févr. 2025, 06:17 UTC

Acquisitions, Fusions, Rachats

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 févr. 2025, 06:16 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 févr. 2025, 06:15 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Anthos Therapeutics

4 févr. 2025, 15:16 UTC

Actualités

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 févr. 2025, 08:12 UTC

Market Talk
Résultats

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 janv. 2025, 13:56 UTC

Résultats

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 janv. 2025, 09:59 UTC

Actions en Tendance

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 janv. 2025, 07:50 UTC

Market Talk

Novartis's Outlook Exceeds Market Views -- Market Talk

31 janv. 2025, 07:46 UTC

Market Talk
Résultats

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 janv. 2025, 06:03 UTC

Résultats

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 janv. 2025, 06:02 UTC

Résultats

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 janv. 2025, 06:02 UTC

Résultats

Novartis Issues 2025 View

31 janv. 2025, 06:02 UTC

Résultats

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 janv. 2025, 06:02 UTC

Résultats

Novartis 4Q Oper Pft $3.53B

31 janv. 2025, 06:02 UTC

Résultats

Novartis 4Q Net Pft $2.82B

31 janv. 2025, 06:02 UTC

Résultats

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 janv. 2025, 06:02 UTC

Résultats

Novartis 4Q Core Operating Profit $4.86B

Comparaison

Variation de prix

Novartis AG prévision

Objectif de Prix

By TipRanks

0.21% hausse

Prévisions sur 12 Mois

Moyen 111 USD  0.21%

Haut 125 USD

Bas 97 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

109.97 / 112.06Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.